论文部分内容阅读
自2005年起,美国临床肿瘤学会(American Society of Clinical Oncology,ASCO)每年都会对本年度一些临床研究进展进行独立回顾,以记录临床肿瘤学研究中的突出进展和显著趋势。这些研究进展在未来可能对肿瘤的诊疗产生较大影响。2012年12月3日,ASCO在《临床肿瘤学杂志》上在线发布了《ASCO临床抗肿瘤进展年度报告:2012临床肿瘤学进展》。该报告共纳科了87项进展,其中17项为重大进展(major advances),其余为主要进展(notable advances)。在过去一年中,主要的进展集中在克服耐药性、实现个性化治疗以及肿瘤筛查等领域。本综述将简要介绍报告中所涉及的一些临床肿瘤进展。
Since 2005, the American Society of Clinical Oncology (ASCO) annually reviews some of the clinical research advances of the current year to document outstanding advances and significant trends in clinical oncology research. These advances in the future may have a greater impact on the diagnosis and treatment of cancer. On December 3, 2012, ASCO released the ASCO Clinical Oncology Progress Report 2012: Progress in Clinical Oncology online at the Journal of Clinical Oncology. In the report, 87 advances were made, of which 17 were major advances and the rest were notable advances. In the past year, major advances have focused on areas such as drug resistance resistance, personalized treatment and oncology screening. This review will outline some of the clinical tumor advances covered in the report.